Pfizer CEO: 4th inoculation is "necessary" and to develop vaccine for all mutant strains

Recently CNN.co.jp reported the following:

ファイザーＣＥＯ、４回目接種は「必要」　全変異株対応のワクチン開発も

2022.03.14 Mon posted at 15:55 JST

  （ＣＮＮ） 米ファイザーのブーラ最高経営責任者（ＣＥＯ）は新型コロナウイルスのワクチンについて、流行の再発を防ぐためには当面４回目の接種が必要との見方を示す一方、あらゆる変異株に対応するワクチンの開発も進めていると語った。

同氏は１３日、米ＣＢＳテレビの番組で、今後多くの変異株が登場するだろうと述べ、オミクロン株はワクチンの効果を巧みにすり抜ける最初の例だと指摘。オミクロン株への現行ワクチンの効果について、入院や死亡はかなり予防できるものの、３回接種後も感染予防はあまり期待できず持続期間も長くないと語り、４回目接種の必要性に言及した。

米国では現在、これまでにファイザーまたは米モデルナ製のワクチンを３回接種した人のうち、免疫不全患者については４回目の接種が認められている。食品医薬品局（ＦＤＡ）が今後、健康な１０代や成人への４回目接種を承認するかどうかは不透明だ。

５～１１歳の子どもについては２回の接種が承認されているが、追加接種は未承認。ファイザーが現在、臨床試験を進めている。

５歳未満の子どもには接種自体が承認されていない。ファイザーが子ども向けの分量を２回接種した臨床試験の初期データでは、２～５歳への効果が予想を下回ったため、現在は３回接種の試験が進行中だ。ブーラ氏によれば、来月には結果が出るとみられ、ＦＤＡの承認を得て５月に接種が始まる可能性もある。

ファイザーとモデルナは現在、オミクロン株に特化したワクチンを開発中だが、ブーラ氏はさらに、全変異株に対応するワクチンの開発を目指すと表明。効果が少なくとも１年間持続するワクチンをつくることが目標だと述べた。

Translation

  (CNN) Pfizer CEO Bourla said that about the vaccine for the new coronavirus, it would require a fourth dose to prevent a recurrence of the epidemic. He said that he was also developing a vaccine for all mutant strains.

He said in a CBS TV show yesterday that many mutant strains could appear in the future, pointing out that the Omicron strain was the first example of a skillful evasion of the vaccine's effects. Regarding the effect of the current vaccine on the Omicron strain, he said that although hospitalization and death could be prevented considerably, infection prevention could not be expected much even after the third vaccination and prevention duration was not long, and he mentioned the need for the fourth vaccination.

In the United States, among those who were vaccinated with Pfizer or US Moderna vaccine three times, the fourth vaccination was currently permitted for immunocompromised patients. It was unclear whether the Food and Drug Administration (FDA) might approve a fourth dose to healthy teens and adults in the future.

Two doses were approved for children aged 5 to 11 years, but booster doses had not been approved. Pfizer was currently doing clinical trials.

Inoculation itself was not approved for children under 5 years of age. Initial data from Pfizer's two-dose clinical trials for children showed less than expected effects on children aged 2 to 5, so a three-dose study was currently underway. According to Bourla, results could be expected next month, and after getting the FDA's approval vaccination could start in May.

Pfizer and Moderna were currently developing a vaccine specifically for the Omicron strain, but Bula also stated that he would aim to develop a vaccine for all mutant strains. He said his goal was to create a vaccine that would last for at least one year.

              So, Pfizer is going to develop a vaccine for all Covid-19 mutant strains that can provide protection for one year. I am looking forward to that vaccine.